| All Releases |
 |
Sunesis to Present at the Jefferies 3rd Annual Healthcare Conference
Jun 16, 2009
|
8.3 KB |
| |
SOUTH SAN FRANCISCO, Calif., June 16, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS), a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers, today announced that Daniel Swisher, Chief Executive ...
|
|
Sunesis Pharmaceuticals Presents Voreloxin Clinical Data at the American Society of Clinical Oncology 2009 Annual Meeting
Jun 1, 2009
|
21.9 KB |
| |
SOUTH SAN FRANCISCO, Calif., June 1, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS), announced today new data from three ongoing clinical trials demonstrating that Sunesis' lead drug candidate, voreloxin, shows promising safety and efficacy in acute myeloid leukemia (AML) and in platinum-resistan...
|
|
Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia and Ovarian Cancer Will Be Presented at ASCO
May 26, 2009
|
12.2 KB |
| |
SOUTH SAN FRANCISCO, Calif., May 26, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS), a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics, today announced that updated interim data from the Company's ongoing Phase 2 clinical trials in frontline...
|
|
Sunesis Pharmaceuticals Receives Extension From NASDAQ to Regain Listing Compliance
May 18, 2009
|
9.3 KB |
| |
SOUTH SAN FRANCISCO, Calif., May 18, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) announced today that on May 13, 2009, it received a letter from The NASDAQ Stock Market notifying Sunesis that it had been granted an extension of time to regain compliance with the minimum $10 million stockholder...
|
|
Sunesis Reports Financial Results for the First Quarter 2009
May 6, 2009
|
37.9 KB |
| |
SOUTH SAN FRANCISCO, Calif., May 6, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today reported financial results for the first quarter ended March 31, 2009.
Total revenue for the first quarter of 2009 was $0.2 million, with a net loss of $8.4 million, including $1.9 million of restructuring c...
|
|
Sunesis Pharmaceuticals Receives NASDAQ Notification
Apr 17, 2009
|
10.7 KB |
| |
SOUTH SAN FRANCISCO, Calif., April 17, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) reported today that it received a letter, dated April 14, 2009, from the Listing Qualifications Department of The NASDAQ Stock Market notifying the Company that it does not comply with the $10.0 million minimum ...
|
|
Sunesis Pharmaceuticals Announces Up To $43.5 Million Financing
Apr 1, 2009
|
14.2 KB |
| |
SOUTH SAN FRANCISCO, Calif., April 1, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced the execution of a securities purchase agreement with accredited investors providing for a private placement of up to $43.5 million in a tranched financing, including two tranches of units consist...
|
|
Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2008 Financial Results
Apr 1, 2009
|
22.6 KB |
| |
SOUTH SAN FRANCISCO, Calif., April 1, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today reported financial results for the fourth quarter and fiscal year ended December 31, 2008.
Total revenue for the year ended December 31, 2008 was $5.4 million, with a net loss of $37.2 million. As of Decem...
|
|
Sunesis Pharmaceuticals Announces the Sale of its LFA-1 Inhibitor Program to SARcode Corporation
Mar 9, 2009
|
10.9 KB |
| |
SOUTH SAN FRANCISCO, Calif., March 9, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that it has sold to SARcode its intellectual property and other assets in its LFA-1 inhibitor program previously licensed to SARcode for a total cash consideration of $2 million. As a result of t...
|
|
Sunesis to Present at the 11th Annual BIO CEO & Investor Conference
Feb 4, 2009
|
8.1 KB |
| |
SOUTH SAN FRANCISCO, Calif., Feb 04, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis
Pharmaceuticals, Inc. (Nasdaq: SNSS), a biopharmaceutical company focused on
the development and commercialization of new oncology therapeutics for the
treatment of solid and hematologic cancers, today announced that the company
will be presentin...
|
|
Sunesis Pharmaceuticals Provides Year-End Clinical Update on Voreloxin
Jan 12, 2009
|
15.0 KB |
| |
SOUTH SAN FRANCISCO, Calif., Jan 12, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today provided a clinical update on voreloxin, its novel investigational drug candidate currently being developed in Phase 2 trials for acute myeloid leukemia (AML) and ovarian cancer. The clinical update coincid...
|
|
Sunesis Pharmaceuticals Announces Presentation of Voreloxin Clinical Data in Patients with Acute Myeloid Leukemia at the 50th Annual Meeting of the American Society of Hematology
Dec 7, 2008
|
16.0 KB |
| |
SAN FRANCISCO, Dec 07, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- --Complete Remissions Achieved with Voreloxin in Poor Risk Frontline Elderly AML and in Combination with Cytarabine in Relapsed/Refractory AML-
--Conference Call Scheduled for Tuesday, December 9 at 11:00 am ET to Discuss Phase 2 Study Results in AML--
Sunesis Pharmaceu...
|
|
Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia To Be Presented at ASH
Dec 1, 2008
|
11.7 KB |
| |
SOUTH SAN FRANCISCO, Calif., Dec 01, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- -- Conference Call Scheduled for Tuesday, December 9 at 11:00 am ET to Discuss Phase 2 Study Results in AML --
Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS), a biopharmaceutical company focused on the development and commercialization of new oncology therape...
|
|
Sunesis to Present at Upcoming Conferences
Nov 25, 2008
|
8.4 KB |
| |
SOUTH SAN FRANCISCO, Calif., Nov 25, 2008 /PRNewswire via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS), a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers, today announced that the company will be presenting at the follo...
|
|
Sunesis Pharmaceuticals Presents Clinical Trial Data of Voreloxin in Patients with Acute Myeloid Leukemia and Ovarian Cancer at the Chemotherapy Foundation Symposium
Nov 6, 2008
|
15.1 KB |
| |
SOUTH SAN FRANCISCO, Calif., Nov 06, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) presented data from three clinical trials of the company's lead drug candidate, voreloxin (formerly SNS-595), at the Chemotherapy Foundation Symposium held in New York on November 4-8. Data previously presented fr...
|
|
Sunesis Reports Financial Results for the Third Quarter 2008
Nov 4, 2008
|
17.0 KB |
| |
SOUTH SAN FRANCISCO, Calif., Nov 04, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today reported financial results for the third quarter ending September 30, 2008.
Total revenue for the third quarter of 2008 was $0.5 million, with a net loss of $7.1 million. As of September 30, 2008, cash, ...
|
|
Sunesis to Present at Upcoming Conferences
Nov 3, 2008
|
9.5 KB |
| |
SOUTH SAN FRANCISCO, Calif., Nov 03, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS), a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers, today announced that the company will be presenting at...
|
|
Sunesis Pharmaceuticals Announces Third Quarter Teleconference and Webcast on November 4, 2008
Oct 28, 2008
|
8.7 KB |
| |
SOUTH SAN FRANCISCO, Calif., Oct 28, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS), a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics, today announced that management will webcast a teleconference to review third quarter progress and provid...
|
|
Sunesis Announces Updated Clinical Data of Voreloxin in Platinum-Resistant Ovarian Cancer
Oct 27, 2008
|
17.5 KB |
| |
SOUTH SAN FRANCISCO, Calif., Oct 27, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced a presentation of updated interim results from an ongoing Phase 2 clinical trial demonstrating that the Company's lead product candidate, voreloxin, shows promising efficacy and safety as a single ...
|
|
Sunesis Announces Multiple Clinical Data Presentations
Oct 21, 2008
|
11.2 KB |
| |
SOUTH SAN FRANCISCO, Calif., Oct 21, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, today announced upcoming data and corporate presentations. Voreloxin mechanism of action...
|
|
|
